Wolf Popper LLP, the law firm that filed the initial complaint against Amarin Corp. plc in the U.S. District Court for New Jersey, is continuing its investigation into allegations contained in the class action lawsuit against Amarin and Joseph S. Zakrzewski (Amarin’s CEO), on behalf of persons who purchased Amarin securities on the U.S. markets, or pursuant to Registration Statements filed with the SEC, during the period July 9, 2009 through October 15, 2013. Wolf Popper’s Complaint charges that defendants misrepresented the prospects for FDA approval of Amarin’s Vascepa drug for the ANCHOR indication and failed to disclose that the FDA had informed Amarin that there was a lack of prospective, controlled clinical trial data demonstrating that pharmaceutical reduction of triglycerides significantly reduces residual cardiovascular risk. Persons who purchased Amarin securities during the Class Period and have losses in excess of $100,000 are urged to contact Wolf Popper to discuss their rights. Other law firms that have issued press releases have not filed complaints and are merely providing investors with notice of Wolf Popper’s lawsuit. Wolf Popper has already been retained by investors with losses over $100,000 to prosecute the class action on their behalf as lead plaintiffs. Investors who purchased Amarin ADRs on the secondary offerings through underwriters on January 6, 2011 at $7.60, or on July 10, 2013 at $5.60, are specifically urged to contact Wolf Popper to discuss their legal rights to pursue claims against the underwriters of those offerings. If you are a member of the Class, you may move the Court no later than January 3, 2014 to appoint you as lead plaintiff. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. To be appointed lead plaintiff, the Court must decide that your claim is typical of the claims of other class members, and that you will adequately represent the class.